CAS: 720702-41-0; (1-Methyl-1H-Pyrazol-5-yl)Boronic Acid

相似化合物

847818-74-0 1217500-54-3 847818-68-2

1-甲基吡唑置于正丁基锂,硼酸三甲酯,Ammonium Chloride体系中,用 四氢呋喃,正己烷 作为反应溶剂,化学反应 2.5H,以38%的收率获得产物1-甲基-1H-吡唑-5-硼酸
参考文献:1-烷基-1 H-吡唑-5-基和1烷基-1 H-吡唑-4-基硼酸频哪醇酯的合成
标题:1-烷基-1 H-吡唑-5-基和1烷基-1 H-吡唑-4-基硼酸频哪醇酯的合成
摘要:从1 H-吡唑开始,合成并表征了多种1-烷基-1 H-吡唑-4-基和1-烷基-1 H-吡唑-5-基硼酸及其频哪醇酯.所述方法中的关键步骤是吡唑环的区域选择性锂化.合成的松果酸酯在长期保存下是稳定的,可以用作有机合成中的方便试剂.
DOI:10.1002/jhet.5570410612

专利信息

专利号:US-2024409557-A1
优先权日:2023-05-09
标 题 :5,6-fused and 6,6-fused bicyclic alcohols and ethers and compositions for use as 15-prostaglandin dehydrogenase modulators
发明人：GREENMAN KEVIN LLOYD; PICKRELL ALEXANDER J; LI KEXUE; AMEGADZIE ALBERT K; WANG HUI-LING; WEIRES NICHOLAS ANTHONY; ALLEN JOHN G; BOURBEAU MATTHEW P
权利人:AMGEN INC
摘要:The present disclosure provides novel 15-hydroxy-prostaglandin dehydrogenase inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions in treating 15-hydroxy-prostaglandin dehydrogenase-mediated disease. Also provided are methods of making such compounds and intermediates thereof. The compounds have a general Formula (A).Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (A).

专利号:WO-2025119326-A1
优先权日:2023-12-07
标 题 :Novel prmt5 inhibitor and use thereof
发明人：YAO BING; WANG MINGHUA; ZHANG JUNQING; GU XIAOHUI; XIE SHANSHAN; CHENG KAI
权利人:SHANGHAI APEIRON THERAPEUTICS COMPANY LTD
摘要:The present disclosure describes novel molecules with protein arginine methyltransferase 5 inhibitory activity, and methods for synthesis and use of the compound. Specifically, the present disclosure describes the compound of formula (I) or a pharmaceutically acceptable salt, hydrate or solvate thereof, and methods for synthesis and use of the compound.

专利号:US-12103929-B2
优先权日:2018-06-25
标题:Tricyclic compounds
发明人：FANG HAIQUAN; CHEN MINGMING; YANG GUIQUN; DU YUELEI; WANG YANPING; WU TONG; LI QINGLONG; ZHANG LEI; HU SHAOJING
权利人:JACOBIO PHARMACEUTICALS CO LTD
摘要:Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.